Allergan Inc (AGN.N)
98.02USD
24 May 2013
$0.06 (+0.06%)
$97.96
$97.58
$98.57
$96.89
587,503
454,161
$116.44
$81.28
AGN.N
About
Overall
| Beta: | 0.81 |
| Market Cap (Mil.): | $29,053.17 |
| Shares Outstanding (Mil.): | 296.40 |
| Dividend: | 0.05 |
| Yield (%): | 0.20 |
Financials
| AGN.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.22 | 34.14 | 34.28 |
| EPS (TTM): | 3.74 | -- | -- |
| ROI: | 14.42 | 19.49 | 18.85 |
| ROE: | 21.09 | 20.26 | 19.72 |
Allergan delays drug that would rival Regeneron's Eylea
- Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea
May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
Allergan delays eye drug, shares fall
- Allergan Inc , maker of the Botox anti-wrinkle treatment, said it will delay late-stage trials of its highly anticipated eye drug Darpin, sending its shares down 14 percent.
BRIEF-Regeneron Pharma shares resume trading, up 16 percent
NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval
BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3
NEW YORK, May 1 - Allergan Inc : * Resumes trading down 11.5 percent after company says phase 2 Darpin eye drug data does not support directly moving to phase 3
Strong Botox sales boost Allergan profit
- Allergan Inc , maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.
Strong Botox sales boost Allergan profit
May 1 - Allergan Inc, maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.
FDA staff says Allergan's new dermal filler effective
April 30 - Reviewers for the U.S. Food and Drug Administration said Allergan Inc's dermal filler, Juvéderm Voluma XC, was effective in correcting volume deficit in the middle of the face at six months of treatment.
Fraudulent versions of Allergan's Botox found in U.S.
- Fraudulent versions of the wrinkle treatment Botox, which is made by Allergan Inc and also used to treat headaches, underarm sweating and overactive bladder, are being sold in the United States, the Food and Drug Administration said on Friday.
UPDATE 3-Fraudulent versions of Allergan's Botox found in U.S.
April 26 - Fraudulent versions of the wrinkle treatment Botox, which is made by Allergan Inc and also used to treat headaches, underarm sweating and overactive bladder, are being sold in the United States, the Food and Drug Administration said on Friday.
Competitors
| Price | Change | |
|---|---|---|
| Alcon, Inc. (ACL.N) | -- | -- |
| Pfizer Inc. (PFE.N) | $29.04 | -0.07 |
| Novartis AG (NOVN.VX) | CHF71.25 | -0.20 |
| Merck & Co., Inc. (MRK.N) | $47.16 | -0.17 |
| Medicis Pharmaceutical Corp (MRX.N) | -- | -- |
| Johnson & Johnson (JNJ.N) | $86.82 | -0.39 |
| Obagi Medical Products, Inc. (OMPI.OQ) | -- | -- |
| L'oreal S.A (OREP.PA) | €132.95 | -0.80 |
| Actavis Inc (ACT.N) | $127.23 | -0.85 |
| Astellas Pharma Inc (4503.T) | ¥5,410 | -70.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (AGN). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
